help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yano, K.
Right arrow Articles by Cutler, G. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yano, K.
Right arrow Articles by Cutler, G. B., Jr

Journal of Clinical Endocrinology & Metabolism, Vol 80, 1162-1168, Copyright © 1995 by Endocrine Society


ARTICLES

A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty

K Yano, M Saji, A Hidaka, N Moriya, A Okuno, LD Kohn and GB Cutler Jr
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

A single point mutation that encodes an aspartic acid (Asp578) to glycine substitution in the LH/CG receptor (LH/CGR) gene, D578G, was recently found in American patients with familial male-limited precocious puberty and in a Japanese patient with a sporadic form of the disorder. Transfection of the mutant, compared to the wild-type, LH/CGR complementary DNA into COS-7 cells results in higher basal cAMP production, but a normal agonist-induced response; the mutation is, therefore, proposed to constitutively activate Leydig cells and elevate serum testosterone, despite low levels of gonadotropin. In the current study we examined two additional Japanese patients with male-limited precocious puberty without a family history of the disease. We describe a heterozygous cytosine (C) to thymine (T) transition at nucleotide 1715 in both; the mutation encodes an alanine to valine substitution in codon 572 of transmembrane helix 6, A572V. Transfected into COS-7 cells, the A572V mutant exhibited the same constitutively high basal cAMP levels and normal agonist-induced cAMP response as the D578G mutant. We conclude that the constitutively higher cAMP levels caused by the A572V mutation led to Leydig cell activation and male-limited precocious puberty, as in the previously described D578G mutation. As the mother of one of the two patients had the same heterozygous mutation, this patient represents the first recognized case of inherited male-limited precocious puberty in the Japanese population. The previously described D578G mutant did not increase basal or agonist- induced inositol phosphate production in transfected COS-7 cells, or the number of LH/CGRs or their affinity for LH/CG. In contrast, transfection of the A572V mutation in COS-7 cells exhibited significantly higher inositol phosphate levels basally and at 10(-11) mol/L hCG, but significantly lower inositol phosphate levels at 10(-7) mol/L hCG. These data suggest that the A572V mutation of the LH/CGR may have effects on the guanine nucleotide binding protein which activates phospholipase C (Gq) coupling and phospholipase-C activation in addition to its effects on Gs coupling and activation of adenylyl cyclase. A572V-transfected cells also exhibited a higher affinity, despite an apparent decrease in the number of binding sites, for [125I]hCG, compared to transfectants with the wild-type LH/CGR. We hypothesize that these differences between the A572V and D578G mutations reflect a greater impact of the A572V mutation on receptor conformation.


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
V. Binet, B. Duthey, J. Lecaillon, C. Vol, J. Quoyer, G. Labesse, J.-P. Pin, and L. Prezeau
Common Structural Requirements for Heptahelical Domain Function in Class A and Class C G Protein-coupled Receptors
J. Biol. Chem., April 20, 2007; 282(16): 12154 - 12163.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
P. G. McDONOUGH
Molecular Abnormalities of FSH and LH Action
Ann. N.Y. Acad. Sci., November 1, 2003; 997(1): 22 - 34.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. B. Seminara and W. F. Crowley Jr.
Genetic Approaches to Unraveling Reproductive Disorders: Examples of Bedside to Bench Research in the Genomic Era
Endocr. Rev., June 1, 2002; 23(3): 382 - 392.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. J. Greasley, F. Fanelli, O. Rossier, L. Abuin, and S. Cotecchia
Mutagenesis and Modelling of the alpha 1b-Adrenergic Receptor Highlight the Role of the Helix 3/Helix 6 Interface in Receptor Activation
Mol. Pharmacol., May 1, 2002; 61(5): 1025 - 1032.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Ascoli, F. Fanelli, and D. L. Segaloff
The Lutropin/Choriogonadotropin Receptor, A 2002 Perspective
Endocr. Rev., April 1, 2002; 23(2): 141 - 174.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. P. N. Themmen and I. T. Huhtaniemi
Mutations of Gonadotropins and Gonadotropin Receptors: Elucidating the Physiology and Pathophysiology of Pituitary-Gonadal Function
Endocr. Rev., October 1, 2000; 21(5): 551 - 583.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
K. Angelova, P. Narayan, J. P. Simon, and D. Puett
Functional Role of Transmembrane Helix 7 in the Activation of the Heptahelical Lutropin Receptor
Mol. Endocrinol., April 1, 2000; 14(4): 459 - 471.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Schipani, C. Langman, J. Hunzelman, M. Le Merrer, K. Y. Loke, M. J. Dillon, C. Silve, and H. Jüppner
A Novel Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor Mutation in Jansen's Metaphyseal Chondrodysplasia
J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3052 - 3057.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Kremer, J. W. M. Martens, M. van Reen, M. Verhoef-Post, J. M. Wit, B. J. Otten, S. L. S. Drop, H. A. Delemarre-van de Waal, M. Pombo-Arias, F. De Luca, et al.
A Limited Repertoire of Mutations of the Luteinizing Hormone (LH) Receptor Gene in Familial and Sporadic Patients with Male LH-Independent Precocious Puberty
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 1136 - 1140.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. C. Latronico, A. N. Abell, I. J. P. Arnhold, X. Liu, T. S. S. Lins, V. N. Brito, A. E. Billerbeck, D. L. Segaloff, and B. B. Mendonca
A Unique Constitutively Activating Mutation in Third Transmembrane Helix of Luteinizing Hormone Receptor Causes Sporadic Male Gonadotropin-Independent Precocious Puberty
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2435 - 2440.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Beinborn, S. M. Quinn, and A. S. Kopin
Minor Modifications of a Cholecystokinin-B/Gastrin Receptor Non-peptide Antagonist Confer a Broad Spectrum of Functional Properties
J. Biol. Chem., June 5, 1998; 273(23): 14146 - 14151.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. Lu, D. I. Vage, and R. D. Cone
A Ligand-Mimetic Model for Constitutive Activation of the Melanocortin-1 Receptor
Mol. Endocrinol., April 1, 1998; 12(4): 592 - 604.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Yano, L. D. Kohn, M. Saji, A. Okuno, and G. B. Cutler Jr.
Phe576 Plays an Important Role in the Secondary Structure and Intracellular Signaling of the Human Luteinizing Hormone/Chorionic Gonadotropin Receptor
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2586 - 2591.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Misrahi, G. Meduri, S. Pissard, C. Bouvattier, I. Beau, H. Loosfelt, A. Jolivet, R. Rappaport, E. Milgrom, and P. Bougneres
Comparison of Immunocytochemical and Molecular Features with the Phenotype in a Case of Incomplete Male Pseudohermaphroditism Associated with a Mutation of the Luteinizing Hormone Receptor
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2159 - 2165.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. A. Bradbury, N. Kawate, C. M. Foster, and K. M.J. Menon
Post-translational Processing in the Golgi Plays a Critical Role in the Trafficking of the Luteinizing Hormone/Human Chorionic Gonadotropin Receptor to the Cell Surface
J. Biol. Chem., February 28, 1997; 272(9): 5921 - 5926.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kosugi, T. Mori, and A. Shenker
The Role of Asp578 in Maintaining the Inactive Conformation of the Human Lutropin/Choriogonadotropin Receptor
J. Biol. Chem., December 13, 1996; 271(50): 31813 - 31817.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Kudo, Y. Osuga, B. K. Kobilka, and A. J.W. Hsueh
Transmembrane Regions V and VI of the Human Luteinizing Hormone Receptor Are Required for Constitutive Activation by a Mutation in the Third Intracellular Loop
J. Biol. Chem., September 13, 1996; 271(37): 22470 - 22478.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society